Literature DB >> 22547106

Tumour characteristics among women with very low-risk breast cancer.

S A Narod1, A Valentini, S Nofech-Mozes, P Sun, W Hanna.   

Abstract

It has been proposed that a proportion of non-palpable breast cancers that are diagnosed through mammography represents a very low-risk subgroup of cancers that may not affect survival (overdiagnosis). The salient pathologic features of cancers in this theoretical subgroup are not known, and therefore, it is not possible to predict which patients have a cancer of this type. We reviewed the clinical characteristics and survival experiences of 715 patients with an invasive breast cancer of 5.0 cm or less. The tumour from each patient was represented in triplicate on a tissue microarray. Cases were divided into low-risk and moderate-/high-risk categories based on lymph node status and palpability. Low-risk cancers were those that were non-palpable, node-negative and were only detected by mammographic screening. All other cancers were high/moderate risk. The two groups of cancer patients were compared for a number of tumour characteristics, based on immunohistochemistry. There were 79 low-risk cancers and 636 moderate-/high-risk cancers. The low-risk cancers were characterized by ER-positivity, PR-positivity, HER2-negativity, ck5/6-negativity, EGFR-negativity and p53-negativity. About 54 of the 79 low-risk cancers (68 %) were of the luminal A subtype versus 335 of 636 moderate-/high-risk cancers (53 %; p = 0.008). Among 42 women with a non-palpable, mammogram-detected PR+ HER2- cancer of 5.0 cm or less, the 15-year distant recurrence-free survival rate was 100 %. Small breast cancers that are PR+ and HER2- and that are detectable by mammogram alone have a very low risk of recurrence. A proportion of these may represent examples of overdiagnosis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22547106     DOI: 10.1007/s10549-012-2065-x

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  6 in total

1.  Overdiagnosis in breast cancer chemoprevention trials.

Authors:  V Sopik; S A Narod
Journal:  Curr Oncol       Date:  2015-02       Impact factor: 3.677

2.  Size surprise? Tumour size, nodal status, and outcome after breast cancer.

Authors:  W D Foulkes
Journal:  Curr Oncol       Date:  2012-10       Impact factor: 3.677

3.  Breast cancer: The importance of overdiagnosis in breast-cancer screening.

Authors:  Steven Narod
Journal:  Nat Rev Clin Oncol       Date:  2015-11-17       Impact factor: 66.675

4.  A comparison of the risks of in-breast recurrence after a diagnosis of dcis or early invasive breast cancer.

Authors:  S A Narod; E Rakovitch
Journal:  Curr Oncol       Date:  2014-06       Impact factor: 3.677

5.  St Gallen molecular subtypes in screening-detected and symptomatic breast cancer in a prospective cohort with long-term follow-up.

Authors:  A K Falck; A Röme; M Fernö; H Olsson; G Chebil; P O Bendahl; L Rydén
Journal:  Br J Surg       Date:  2016-02-09       Impact factor: 6.939

6.  Tumor biology, clinicopathological characteristics and prognosis of screen detected T1 invasive non-palpable breast cancer in asymptomatic Chinese women (2001-2014).

Authors:  Bo Pan; Ru Yao; Yi-Dong Zhou; Qing-Li Zhu; Jie Shi; Qian-Qian Xu; Chang-Jun Wang; Shan-Shan You; Feng Mao; Yan Lin; Song-Jie Shen; Zhi-Yong Liang; Yu-Xin Jiang; Qiang Sun
Journal:  Oncotarget       Date:  2017-04-18
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.